UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

Clinical cancer research, 2018-04, Vol.24 (8), p.1816-1823

2018

Volltextzugriff (PDF)

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Clinical cancer research, 2017-09, Vol.23 (18), p.5349-5357

2017

Volltextzugriff (PDF)

A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2019-12, Vol.7 (1), p.342-11, Article 342

2019

Volltextzugriff (PDF)

Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study

Targeted oncology, 2021-11, Vol.16 (6), p.761-771

2021

Volltextzugriff (PDF)

Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma

Journal of clinical oncology, 2005-07, Vol.23 (19), p.4390-4398

2005

Volltextzugriff (PDF)

The α(1,3)Fucosyltransferase Fuc-TVII Controls Leukocyte Trafficking through an Essential Role in L-, E-, and P-selectin Ligand Biosynthesis

Cell, 1996-08, Vol.86 (4), p.643-653

1996

Volltextzugriff (PDF)

Elimination of Porcine Hemopoietic Cells by Macrophages in Mice

The Journal of immunology (1950), 2002-01, Vol.168 (2), p.621-628

2002

Volltextzugriff (PDF)

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20 + Non-Hodgkin Lymphomas

Clinical cancer research, 2020-06, Vol.26 (11), p.2524-2534

2020

Volltextzugriff (PDF)

Mac-1-Negative B-1b Phenotype of Natural Antibody-Producing Cells, Including Those Responding to Galα1,3Gal Epitopes in α1,3-Galactosyltransferase-Deficient Mice

The Journal of immunology (1950), 2000-11, Vol.165 (10), p.5518-5529

2000

Volltextzugriff (PDF)

Tolerization of Anti–Galα1-3Gal Natural Antibody–forming B Cells by Induction of Mixed Chimerism

The Journal of experimental medicine, 1998-04, Vol.187 (8), p.1335-1342

1998

Volltextzugriff (PDF)

Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial

Blood advances, 2021-09, Vol.5 (17), p.3387-3396

2021

Volltextzugriff (PDF)

Avelumab (MSB0010718C; anti-PD-L1) in combination with other cancer immunotherapies in patients with advanced malignancies: The phase 1b/2 JAVELIN Medley study

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS3106-TPS3106

2016

Volltextzugriff (PDF)

Blockade of CD28-B7, But Not CD40-CD154, Prevents Costimulation of Allogeneic Porcine and Xenogeneic Human Anti-Porcine T Cell Responses

The Journal of immunology (1950), 2000-03, Vol.164 (6), p.3434-3444

2000

Volltextzugriff (PDF)

P-selectin Glycoprotein Ligand-1 and E-selectin Ligand-1 Are Differentially Modified by Fucosyltransferases Fuc-TIV and Fuc-TVII in Mouse Neutrophils

The Journal of biological chemistry, 2000-10, Vol.275 (40), p.31353-31360

2000

Volltextzugriff (PDF)

Oocyte Galα1,3Gal Epitopes Implicated in Sperm Adhesion to the Zona Pellucida Glycoprotein ZP3 Are Not Required for Fertilization in the Mouse (∗)

The Journal of biological chemistry, 1995-09, Vol.270 (37), p.21437-21440

1995

Volltextzugriff (PDF)

A phase I/II study of sunitinib in young patients with advanced gastrointestinal stromal tumor

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS10601-TPS10601

2014

Volltextzugriff (PDF)

A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3004-3004

2015

Volltextzugriff (PDF)

Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases

Journal of thoracic oncology, 2011-07, Vol.6 (7), p.1260-1266

2011

Volltextzugriff (PDF)

Xenoantigens and Xenoantibodies: Their Modification

World journal of surgery, 1997-11, Vol.21 (9), p.901-906

1997

Volltextzugriff (PDF)

A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.3007-3007

2014

Volltextzugriff (PDF)

Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma

Cancer chemotherapy and pharmacology, 2013-02, Vol.71 (2), p.307-319

2013

Volltextzugriff (PDF)

CLEARANCE OF MOBILIZED PORCINE PERIPHERAL BLOOD PROGENITOR CELLS IS DELAYED BY DEPLETION OF THE PHAGOCYTIC RETICULOENDOTHELIAL SYSTEM IN BABOONS1

Transplantation, 2001-10, Vol.72 (7), p.1278-1285

2001

Volltextzugriff (PDF)

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study

Investigational new drugs, 2013-12, Vol.31 (6), p.1487-1498

2013

Volltextzugriff (PDF)

One Percent of Human Circulating B Lymphocytes Are Capable of Producing the Natural Anti-Gal Antibody

Blood, 1993-10, Vol.82 (8), p.2485-2493

1993

Volltextzugriff (PDF)

Distribution of Gal.alpha.1.fwdarw.3Gal.beta.1.fwdarw.4GlcNAc residues on secreted mammalian glycoproteins (thyroglobulin, fibrinogen, and immunoglobulin G) as measured by a sensitive solid-phase radioimmunoassay

Biochemistry (Easton), 1990-04, Vol.29 (16), p.3959-3965

1990

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(39)
Dissertationen
(2)

Sprache

Englisch
(41)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors

Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study

Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma

The α(1,3)Fucosyltransferase Fuc-TVII Controls Leukocyte Trafficking through an Essential Role in L-, E-, and P-selectin Ligand Biosynthesis

Elimination of Porcine Hemopoietic Cells by Macrophages in Mice

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20 + Non-Hodgkin Lymphomas

Mac-1-Negative B-1b Phenotype of Natural Antibody-Producing Cells, Including Those Responding to Galα1,3Gal Epitopes in α1,3-Galactosyltransferase-Deficient Mice

Tolerization of Anti–Galα1-3Gal Natural Antibody–forming B Cells by Induction of Mixed Chimerism

Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial

Avelumab (MSB0010718C; anti-PD-L1) in combination with other cancer immunotherapies in patients with advanced malignancies: The phase 1b/2 JAVELIN Medley study

Blockade of CD28-B7, But Not CD40-CD154, Prevents Costimulation of Allogeneic Porcine and Xenogeneic Human Anti-Porcine T Cell Responses

P-selectin Glycoprotein Ligand-1 and E-selectin Ligand-1 Are Differentially Modified by Fucosyltransferases Fuc-TIV and Fuc-TVII in Mouse Neutrophils

Oocyte Galα1,3Gal Epitopes Implicated in Sperm Adhesion to the Zona Pellucida Glycoprotein ZP3 Are Not Required for Fertilization in the Mouse (∗)

A phase I/II study of sunitinib in young patients with advanced gastrointestinal stromal tumor

A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL

Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases

Xenoantigens and Xenoantibodies: Their Modification

A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer

Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma

CLEARANCE OF MOBILIZED PORCINE PERIPHERAL BLOOD PROGENITOR CELLS IS DELAYED BY DEPLETION OF THE PHAGOCYTIC RETICULOENDOTHELIAL SYSTEM IN BABOONS1

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study

One Percent of Human Circulating B Lymphocytes Are Capable of Producing the Natural Anti-Gal Antibody

Distribution of Gal.alpha.1.fwdarw.3Gal.beta.1.fwdarw.4GlcNAc residues on secreted mammalian glycoproteins (thyroglobulin, fibrinogen, and immunoglobulin G) as measured by a sensitive solid-phase radioimmunoassay

Suchergebnisse filtern